Introduction to Semaglutide

As global health management becomes a national priority, obesity and diabetes have emerged as rapidly growing public health concerns. According to the World Health Organization, more than 2 billion people worldwide are overweight or obese, while China alone has over 140 million diabetes patients. Metabolic disorders caused by obesity have intensified the demand for solutions that combine healthy weight loss and blood-glucose management.

Against this backdrop, Semaglutide—a long-acting GLP-1 receptor agonist—has become the world’s most prominent metabolic-disease therapeutic. In 2024–2025, Semaglutide demand surged globally, and by Q1 2025, it even surpassed Keytruda to become the world’s best-selling drug. This explosive market demand has accelerated the transformation of manufacturing technologies, shifting from traditional chemical synthesis toward biosynthetic, fermentation-based production.

Biosynthetic semaglutide production requires precision-engineered recombinant peptides and specialized enterokinase processing. Hzymes offers GLP-1(9-37) UltraPure and custom recombinant fermented peptides for semaglutide precursor synthesis.

What Is Semaglutide?

Semaglutide is a GLP-1 analog widely used for weight management and type 2 diabetes treatment. By activating the GLP-1 receptor, it enhances insulin secretion, reduces appetite, slows gastric emptying, and helps patients effectively manage both body weight and blood glucose.

Its efficacy, safety profile, and long half-life have made it a leading molecule in the global metabolic-disease drug market.

Why Traditional Chemical Synthesis Is Limiting

Conventional chemical peptide synthesis requires multiple protection, coupling, and deprotection steps. Challenges include:

Low recovery rate

High production cost

Long manufacturing cycle

As a result, the industry is increasingly adopting biosynthetic methods, which offer higher yields, better scalability, and improved cost-effectiveness for long peptides like Semaglutide.

Biosynthesis: A Breakthrough in Semaglutide Manufacturing

Modern biosynthetic Semaglutide uses prokaryotic or eukaryotic expression systems to generate the core peptide chain via fermentation. The process generally includes:

Expression of a precursor peptide fused with a solubility-enhancing tag

Extraction and purification from fermentation broth

Enzymatic removal of the tag

Chemical conjugation of the N-terminal non-proteinogenic amino acid

Final purification to obtain high-purity Semaglutide

This method significantly shortens production timelines and reduces cost while maintaining high quality and consistency.

HCD/HCP Risk Control: A Critical Quality Requirement

Target peptides in fermentation lysates coexist with impurities such as host proteins, host nucleic acids, and endotoxins. The mainstream purification strategy includes three-step chromatography (affinity – ion exchange – size exclusion).

HCD (host cell DNA) 

consists of DNA fragments derived from E. coli cells. Its biosafety risks include carcinogenicity, infectivity, and immunogenic reactions.

HCP (host cell proteins) 

are highly complex, with more than 2,000 proteins potentially present in an E. coli lysate. Their biosafety risks include protease-mediated degradation of therapeutic proteins and immunogenic reactions.

To ensure product safety, regulatory agencies have established strict limits on residual E. coli HCD and HCP levels.

Application Prospects of Biosynthetic Semaglutide

With the growing global focus on metabolic disease management, Semaglutide and other GLP-1 peptides continue to expand across multiple therapeutic areas:

Weight-loss therapeutics

Type 2 diabetes therapy

Combination metabolic treatment regimens

Development of next-generation GLP-1-based peptide drugs

The biosynthetic production model is poised to become the mainstream route for large-scale Semaglutide API manufacturing, offering high yield, purity, and cost efficiency.

 
Hzymes Biotech Peptide Product Portfolio Supporting Semaglutide Development

01.  Biosynthetic GLP-1 29 Peptide

Hzymes independently develops and manufactures GLP-1 (29 amino acids), expressed recombinantly in E. coli. Following enzymatic cleavage, chromatography purification, and lyophilization, a freeze-dried powder is obtained. Compared to chemical synthesis, this approach enables large-scale continuous production with high purity, low impurities, high yield, and reduced cost.

02. Recombinant Enterokinase (High Specificity)

Recombinant enterokinase (rEK) is produced via genetic engineering, offering high purity, activity, and specificity. It recognizes and cleaves proteins containing the Asp-Asp-Asp-Asp-Lys (DDDDK) motif.

Applications:

• Fusion protein processing in genetic engineering: removes N-terminal tags to ensure proper folding and functionality.
• Peptide drug manufacturing: processes insulin, its analogs, GLP-1, and others by removing N-terminal tags while preserving bioactivity.

03.  E. coli HCD Detection

Hzymes’ E. coli residual DNA detection kit adopts qPCR probe-based technology, combined with automated nucleic acid extraction systems for high-throughput applications. It provides accurate and efficient HCD detection solutions, suitable for quality control at various peptide production stages.

Hzymes recombinant enterokinase enables highly specific cleavage

04. E. coli HCP Detection

Enzyme-linked immunosorbent assay (ELISA) remains the most widely used method for HCP detection. The Chinese Pharmacopoeia recommends ELISA for host protein analysis, while the USP <1132> chapter also highlights ELISA as the preferred method.

Hzymes’ E. coli HCP kit uses a double-antibody sandwich one-step format, reducing detection time to just 2 hours, and enables rapid quantitative analysis of HCP content in samples.

Why Partner with Hzymes for Semaglutide Development

Hzymes provides a complete solution for Semaglutide and GLP-1 peptides:

Biosynthetic GLP-1 29 Peptide 

– high-purity, scalable, cost-effective production

Recombinant Enterokinase 

– precise N-terminal cleavage for active peptides

HCD & HCP Detection Kits 

– rapid, accurate quality control

Scalable Fermentation & Purification 

– continuous, pharmaceutical-grade manufacturing

Partnering with Hzymes ensures safe, efficient, and high-quality Semaglutide production.

Product Ordering